Opendata, web and dolomites

LYMPHVECs SIGNED

Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LYMPHVECs" data sheet

The following table provides information about the project.

Coordinator
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL 

Organization address
address: C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MADRID
city: TRES CANTOS
postcode: 28760
website: www.gsk.es/html/investigacion/espana.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL ES (TRES CANTOS) coordinator 158˙121.00

Map

 Project objective

According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin America. However, nowadays it has been reported worldwide. Benznidazole (BZ) has been recently approved in US (30/08/2017) as the first option treatment for CD but can only administered for 14 days or less, while it is known that at least 2-3 months of treatment are required for full efficacy. This approval for short-term CD therapy is due to the severe side effects associated with extended use, which severely impacts the applicability of BZ as a universal CD treatment.

Importantly, Trypanosoma cruzi (Tc) parasite reservoirs have been localized into the Lymphatic System (LS). Poor compound distribution into the LS could be the reason why extended BZ treatment is required and why reactivation of the parasites in the chronic stage is commonly found.

Chagas infected people treated with BZ develop rashes, fever, nausea, headache, allergic dermatitis, digestive intolerance (anorexia), peripheral neuropathy and insomnia. These severe side effects limit its use and foster non-compliance. BZ formulations that reduce compound exposure in system circulation while facilitating distribution into the LS could reduce the efficacious dose (at present 5-7mg/kg/day), reduce side effects, and possibly contribute treatment shortening. This project will develop BZ formulations based on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to achieve these three goals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHVECS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LYMPHVECS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

lanloss (2020)

Landscapes of Loss: Mapping the Affective Experience of Deforestation Among Diverse Social Groups in the South American Chaco

Read More